Pre-made Bifikafusp benchmark antibody ( Whole mAb Fusion, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bifikafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-068-1mg	1mg	Inquiry
GMP-Bios-ab-068-10mg	10mg	Inquiry
GMP-Bios-ab-068-100mg	100mg	Inquiry
GMP-Bios-ab-068-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bifikafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody
INN Name	Bifikafusp
Target	FN extra domain B
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgE
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Philogen
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours
Conditions Discontinued	Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer
Development Tech	na